Leonard Reyno
Fortune : 118 982 $ au 30/06/2026
Fortune : 118 982 $ au 30/06/2026
Leonard M.
J.
Reyno currently serves as Chief Medical Officer-Oncology at Astellas Pharma US, Inc., is a Member of the American Society of Clinical Oncology, Inc., and holds the position of Chief Medical Officer at C4 Therapeutics, Inc. since 2023.
Former roles include Independent Director at Radient Pharmaceuticals Corp.
from 2011 to 2012, Chief Medical Officer & Senior Vice President at Agensys, Inc., Associate Member at the American Association for Cancer Research, Chief Medical Officer & President-R&D at Pionyr Immunotherapeutics, Inc., and Chief Medical Officer & Executive VP at Oric Pharmaceuticals, Inc. Education includes undergraduate studies at Dalhousie University and a doctorate from McMaster University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
C4 THERAPEUTICS, INC. 0,02 % | 22/04/2026 | 25 478 ( 0,02 % ) | 118 982 $ | 30/06/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| C4 THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 10/07/2023 |
Astellas Pharma US, Inc.
Astellas Pharma US, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Corporate Officer/Principal | 15/09/2011 |
American Society of Clinical Oncology, Inc.
American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services Provides cancer treatment services | Corporate Officer/Principal | 20/09/2011 |
| Sociétés | Poste | Fin |
|---|---|---|
| RADIENT PHARMACEUTICALS CORP | Directeur/Membre du Conseil | 26/06/2012 |
| ORIC PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | - |
Pionyr Immunotherapeutics, Inc.
Pionyr Immunotherapeutics, Inc. BiotechnologyHealth Technology Develops antibody-based Immuno-oncology therapeutics | Directeur Technique/Scientifique/R&D | - |
American Association for Cancer Research
American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services Engages in research, education, communication and collaboration to prevent and cure cancer | Corporate Officer/Principal | - |
Agensys, Inc.
Agensys, Inc. Miscellaneous Commercial ServicesCommercial Services Develops medicines for cancers | Directeur Technique/Scientifique/R&D | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 10 |
|---|---|
Radient Pharmaceuticals Corp.
Radient Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Researches and manufactures pharmaceutical products relating to cancer | Health Technology |
Agensys, Inc.
Agensys, Inc. Miscellaneous Commercial ServicesCommercial Services Develops medicines for cancers | Commercial Services |
Dalhousie University
Dalhousie University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
McMaster University
McMaster University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Astellas Pharma US, Inc.
Astellas Pharma US, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
American Society of Clinical Oncology, Inc.
American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services Provides cancer treatment services | Health Services |
American Association for Cancer Research
American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services Engages in research, education, communication and collaboration to prevent and cure cancer | Commercial Services |
Oric Pharmaceuticals, Inc.
Oric Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops pharmaceutical products | Health Technology |
C4 Therapeutics, Inc.
C4 Therapeutics, Inc. BiotechnologyHealth Technology Develops targeted protein degradation therapeutics for the treatment of cancer | Health Technology |
Pionyr Immunotherapeutics, Inc.
Pionyr Immunotherapeutics, Inc. BiotechnologyHealth Technology Develops antibody-based Immuno-oncology therapeutics | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national